ClinicalTrials.gg
CompletedNCT01458327Updated Jan 24, 2024Results posted

Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial

A Phase 2 interventional study of Midomafetamine and Therapy in Posttraumatic Stress Disorder, sponsored by Lykos Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-24.

Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Dec 2010, registered Oct 2011).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic — 11 open to participants now, 12 under way, 1 of them phase 3. N-Methyl-3,4-methylenedioxyamphetamine · Stress Disorders, Post-Traumatic.

Enrollment
34th of 38
3 · median 25
Started
2010
with 1 other
Phase 2
28 of 38
10 open now
Registered
5th of 38
by date
Lead sponsor
16 of 38
Lykos Therapeutics

Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, this one is the 34th largest by enrollment, is one of 2 that started in 2010, is one of 28 in phase 2, and was the 5th registered.

Stress Disorders, Post-Traumatic

2,688 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 606 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

11 of the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About N-Methyl-3,4-methylenedioxyamphetamine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

This study will consist of a single session of MDMA-assisted therapy with a full dose of MDMA for people who took part in a study of MDMA-assisted therapy in people with posttraumatic stress disorder (PTSD) whose PTSD symptoms returned to higher levels at least a year after the first MDMA sessions. The single session will be performed by the same pair of therapists who performed the sessions in the first study. People will have a preparatory session, the MDMA-assisted session and three non-drug sessions afterward. Their PTSD symptoms and symptoms of depression will be measured at the start of this study and two and 12 months after the session.

Read the detailed description

This study will investigate the effects of an additional 3,4-methylenedioxymethamine (MDMA)-assisted therapy session in up to three participants with PTSD who relapsed after their PTSD symptoms had significantly decreased during MAPS' initial U.S. Phase 2 trial testing the use of MDMA-assisted therapy in subjects with chronic, treatment-resistant posttraumatic stress disorder PTSD). This new protocol will consist of a single, full-dose open-label session of MDMA-assisted therapy, along with associated non-drug preparation and integrative therapy sessions.

MDMA is an investigational drug that was studied in a randomized, placebo-controlled study in 21 participants, and it included a final evaluation of symptoms at least one year after taking part in the study. While PTSD symptoms in most study subjects stayed at the same levels from when they completed the study, symptoms had returned in a few people. This open-label study is intended to see if an additional MDMA-assisted session conducted at least 14 months after the first sessions can help reduce PTSD symptoms.

The MDMA-assisted therapy session will be conducted by a male and female co-therapist team, one a psychiatrist and the other a psychiatric nurse. Vital signs (blood pressure, pulse and body temperature) and psychological distress will be measured throughout the experimental session. After the experimental session they will spend the night in the clinic with an attendant on duty, and complete a measure of alterations in consciousness, the States of Consciousness Questionnaire (SCQ) on the evening or day following the experimental session. Participants will meet with the investigators the next morning for an integrative therapy session before leaving the clinic. During integrative therapy sessions they will receive support in integrating their experiences and insights from the MDMA-assisted therapy session. There will be daily phone contact with one of the investigators for 7 days after the experimental session. Symptoms of PTSD, depression and general function will be assessed two months after the experimental session. There will be a long-term follow up with repeated outcome measures 12 months after the experimental session

03

Conditions studied

  • Posttraumatic Stress Disorder

Keywords

  • MDMA
  • PTSD
  • therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be diagnosed with chronic PTSD;
  • Have a CAPS score showing moderate to severe PTSD symptoms;
  • Have participated in MP-1;
  • Are at least 18 years old;
  • Must be generally healthy;
  • Must sign a medical release for the investigators to communicate directly with their therapist and doctors;
  • Are willing to refrain from taking any psychiatric medications during the study period;
  • Willing to follow restrictions and guidelines concerning consumption of food, beverages, and nicotine the night before and just prior to each experimental session;
  • Willing to remain overnight at the study site;
  • Agree to have transportation other than driving themselves home or to where they are staying after the integrative session on the day after the MDMA session;
  • Are willing to be contacted via telephone for all necessary telephone contacts;
  • Must have a negative pregnancy test if able to bear children, and agree to use an effective form of ;
  • must provide a contact in the event of a participant becoming suicidal;
  • Are proficient in speaking and reading English;
  • agree to have all clinic visit sessions recorded to audio and video
  • Agree not to participate in any other interventional clinical trials during the duration of this study.

Exclusion criteria

Exclusion Criteria:

  • Are pregnant or nursing, or if a woman who can have children, those who are not practicing an effective means of ;
  • Weigh less than 48 kg;
  • Are abusing illegal drugs;
  • Are unable to give adequate ;
  • Upon review of past and current drugs/medication must not be on or have taken a medication that is exclusionary;
  • Upon review of medical or psychiatric history must not have any current or past diagnosis that would be considered a risk to participation in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    MDMA-assisted therapy

    One experimental session of MDMA-assisted therapy

    Drug: Midomafetamine · Behavioral: Therapy

Interventions

  • 125 mg MDMA followed by 62.5 mg MDMA 1.5 to 2.5 hours later

    Also known as: MDMA, 3,4-methylenedioxymethamphetamine

  • BehavioralTherapy

    Non-directive therapy

06

What researchers measure

Primary outcomes

  1. Baseline Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV)

    The CAPS-IV is a structured clinical interview designed to assess the symptoms and severity of PTSD. The CAPS-IV provides a means to evaluate the frequency and intensity dimensions of each symptom, the impact of symptoms on the patient's social and occupational functioning, the overall severity of the symptom complex, global improvement since baseline, and the validity of the ratings obtained. Total severity scores range from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

    Time frame: Less than 4 weeks before first experimental session

  2. Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) at 2-month Follow-up

    The CAPS-IV is a structured clinical interview designed to assess the symptoms and severity of PTSD. The CAPS-IV provides a means to evaluate the frequency and intensity dimensions of each symptom, the impact of symptoms on the patient's social and occupational functioning, the overall severity of the symptom complex, global improvement since baseline, and the validity of the ratings obtained. Total severity scores range from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

    Time frame: 2 months post experimental session

  3. Clinician-Administered PTSD Scale (CAPS-IV)) at 12-month Follow-up

    The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

    Time frame: 12 months post experimental session

  4. Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to 2-month Follow-up

    The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

    Time frame: Baseline to 2 months post experimental session

  5. Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to 12-month Follow-up

    The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

    Time frame: Baseline to 12 months post experimental session

07

Results

Posted Nov 3, 2021

Participant flow

Participant flow — Overall Study
Milestone3,4-methylenedoxymethamphetamine (MDMA)-Assisted Therapy
Started3
Completed3
Not completed0

Outcome measures

PrimaryBaseline Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV)

The CAPS-IV is a structured clinical interview designed to assess the symptoms and severity of PTSD. The CAPS-IV provides a means to evaluate the frequency and intensity dimensions of each symptom, the impact of symptoms on the patient's social and occupational functioning, the overall severity of the symptom complex, global improvement since baseline, and the validity of the ratings obtained. Total severity scores range from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

Time frame:
Less than 4 weeks before first experimental session
Reported as:
Mean · score on a scale
Baseline Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV)
score on a scale3,4-methylenedoxymethamphetamine (MDMA)-Assisted Therapy
Baseline Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV)93.3 ± 1.53
PrimaryClinician-Administered PTSD Scale for DSM-IV (CAPS-IV) at 2-month Follow-up

The CAPS-IV is a structured clinical interview designed to assess the symptoms and severity of PTSD. The CAPS-IV provides a means to evaluate the frequency and intensity dimensions of each symptom, the impact of symptoms on the patient's social and occupational functioning, the overall severity of the symptom complex, global improvement since baseline, and the validity of the ratings obtained. Total severity scores range from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

Time frame:
2 months post experimental session
Reported as:
Mean · score on a scale
Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) at 2-month Follow-up
score on a scale3,4-methylenedoxymethamphetamine (MDMA)-Assisted Therapy
Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) at 2-month Follow-up31.3 ± 12.01
PrimaryClinician-Administered PTSD Scale (CAPS-IV)) at 12-month Follow-up

The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

Time frame:
12 months post experimental session
Reported as:
Mean · score on a scale
Clinician-Administered PTSD Scale (CAPS-IV)) at 12-month Follow-up
score on a scale3,4-methylenedoxymethamphetamine (MDMA)-Assisted Therapy
Clinician-Administered PTSD Scale (CAPS-IV)) at 12-month Follow-up52.7 ± 39.63
PrimaryChange in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to 2-month Follow-up

The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

Time frame:
Baseline to 2 months post experimental session
Reported as:
Mean · score on a scale
Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to 2-month Follow-up
score on a scale3,4-methylenedoxymethamphetamine (MDMA)-Assisted Therapy
Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to 2-month Follow-up-62.0 ± 12.53
PrimaryChange in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to 12-month Follow-up

The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

Time frame:
Baseline to 12 months post experimental session
Reported as:
Mean · score on a scale
Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to 12-month Follow-up
score on a scale3,4-methylenedoxymethamphetamine (MDMA)-Assisted Therapy
Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to 12-month Follow-up-40.7 ± 40.27

Adverse events

Collected over Adverse Events were collected throughout the study for approximately 12 months during Experimental Session (Visit 2), Integrative Sessions (Visit 3-5), 2-month Follow-up (Visit 6), and 12-month Follow-up (Visit7). AE's that occurred prior to date of first experimental dose were not reported.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
3,4-methylenedoxymethamphetamine (MDMA)-Assisted Therapy0/3 (0%)1/3 (33.3%)1/3 (33.3%)
Most frequent serious events
Most frequent serious events
Event3,4-methylenedoxymethamphetamine (MDMA)-Assisted Therapy
Suicidal ideationPsychiatric disorders1/3
Most frequent other events
Most frequent other events
Event3,4-methylenedoxymethamphetamine (MDMA)-Assisted Therapy
Major depressionPsychiatric disorders1/3
Drug abusePsychiatric disorders1/3
DissociationPsychiatric disorders1/3
Upper respiratory tract infectionInfections and infestations1/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)3,4-methylenedoxymethamphetamine (MDMA)-Assisted Therapy
Mean46.9 ± 7.79
Sex: Female, Male
Sex: Female, Male(Participants)3,4-methylenedoxymethamphetamine (MDMA)-Assisted Therapy
Female3
Male0
08

Study locations

1 site
  • Offices of Michael Mithoefer
    Mount Pleasant, South Carolina 29464, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2010 to primary completion in Jun 2014, 42 months.

Results were first posted in Nov 2021, 7 years 4 months after primary completion. A results delay was requested in Aug 2016.

Of 31 industry-sponsored phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 42 months is above that.

Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2011
First posted
Oct 24, 2011
StartActual
Dec 15, 2010
Primary completionActual
Jun 27, 2014
CompletionActual
Jun 27, 2014
Results delay requested
Aug 18, 2016
Results first posted
Nov 3, 2021
Last update
Jan 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01458327
Lead sponsor
Lykos Therapeutics
Responsible party
Sponsor
First posted
Oct 24, 2011
Start date
Dec 15, 2010
Primary completion
Jun 27, 2014
Completion
Jun 27, 2014
Results posted
Nov 3, 2021
Last update
Jan 24, 2024

Study contacts

Michael C Mithoefer, MD
principal investigator · Psychiatrist

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion